Skip to main content

Table 1 Distribution of cell viability percentage according to the treatment, cell line and exposure time.

From: Free Rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy

Treatment Cell line 24 h   48 h   72 h  
0 (control) MCF-7 100.00 ± 1.50 A*; a# 99.94 ± 1.95 A; a 100.00 ± 1.06 A; a
  4T1 100.00 ± 1.21 A; a 100.00 ± 1.46 A; a 100.00 ± 1.34 A; a
  MCF-10A 100.00 ± 3.30 A; a 100.00 ± 1.05 A; a 100.00 ± 0.92 A; a
Rh 2 (H 2 cit) 4 50 μM MCF-7 94.96 ± 2.44 A; a 97.48 ± 2.84 A; a 81.19 ± 2.30 B; a
  4T1 90.31 ± 1.38 A; a 87.79 ± 2.63 A.B; a 81.42 ± 2.56 B; a
  MCF-10A 97.75 ± 3.77 A; a 97.82 ± 1.40 A; a 84.30 ± 2.55 B; a
Rh 2 (H 2 cit) 4 200 μM MCF-7 89.28 ± 2.60 A; a 81.64 ± 2.38 A; a 70.13 ± 2.58 B; a
  4T1 79.13 ± 1.44 A; b 73.42 ± 2.17 A.B; a 68.12 ± 3.64 B; a
  MCF-10A 61.82 ± 6.54 A; b 44.19 ± 1.60 B; b 30.43 ± 2.69 C; b
Rh 2 (H 2 cit) 4 300 μM MCF-7 85.33 ± 2.14 A; a 73.77 ± 2.58 B; a 54.14 ± 2.47 C; a
  4T1 73.95 ± 2.54 A; a 61.77 ± 1.47 B; b 47.79 ± 4.11 C; a
  MCF-10A 39.41 ± 7.47 A; b 23.81 ± 0.74 B; c 12.78 ± 0.92 C; b
Rh 2 (H 2 cit) 4 500 μM MCF-7 50.08 ± 2.49 A; a 25.29 ± 3.46 B.C; a 30.39 ± 3.47 C; a
  4T1 46.14 ± 3.49 A; a 30.66 ± 1.22 B; a 26.07 ± 2.75 B; a
  MCF-10A 25.85 ± 6.46 A; b 11.62 ± 1.17 A.B; b 5.46 ± 0.46 C; b
Rh 2 (H 2 cit) 4 600 μM MCF-7 28.71 ± 3.90 A; a 16.86 ± 1.77 B; a 12.16 ± 1.93 B; a
  4T1 29.87 ± 3.67 A; a 15.86 ± 0.57 B; a 9.97 ± 1.49 B; a
  MCF-10A 13.34 ± 2.43 A; b 10.26 ± 1.27 A; b 4.76 ± 0.39 B; b
DMSO (0.85%) MCF-7 90.51 ± 5.9 A; a 90.93 ± 1.7 A; a 96.4 ± 1.4 A; a
  4T1 106.2 ± 1.3 A; b 100.6 ± 2.97 A; a 43.07 ± 8.2 B; b
  MCF-10A 148.1 ± 6.8 A; c 82.45 ± 2.3 B; a 63.35 ± 2.2 C; c
Paclitaxel 50 μM MCF-7 70.07 ± 0.4 A; a 55.93 ± 1.6 B; a 18.92 ± 4.3 C; a
  4T1 68.31 ± 1.2 A; a 30.12 ± 0.7 B; b 21.51 ± 1.4 C; a
  MCF-10A 80.17 ± 6.7 A; c 33.52 ± 1.09 B; b 20.95 ± 1.1 C; a
  1. The data represent the mean ± SE (mean standard error) of three independent experiments in triplicates. * Different capital letters denote statistical difference between viability in the different times (rows) for a given cell line (breast cancer cells MCF-7. 4T1 or normal cells MCF-10A) under the same treatment (p <0.05). # Different tiny letters indicate mean statistical difference between the viability of different cell lines (columns) for a given time (24. 48 or 72 hours) (p <0.05).